Affilogic receives research costs and will be eligible to receive development milestones along with royalty on net sales of any product. Apellis gets an exclusive, sublicensable, patent rights globally for all development project
The collaboration will combine Affilogic’s brain shuttle technology with Apellis’ deep expertise in complementing to develop of novel therapies for neurological diseases
The companies are working together to develop Nanofitin-based therapies that specifically target C3. In the next 12mos., Apellis anticipates submitting IND applications for research programs, including 2 pre-clinical products i.e., APL-1030 for neurodegenerative & other complement-driven diseases & APL-2006 for wet AMD and GA
Ref: GlobalNewswire | Image: Apellis
